Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 21, 2018
Pharmacy Choice - News - U.S. Pharmaceutical Industry - October 21, 2018

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/20/18 - 51 Drug Dealers Arrested in Allegheny County Roundup
Pennsylvania Attorney General Josh Shapiro issued the following news release:. Attorney General Josh Shapiro today announced criminal charges against 51 people for selling heroin, fentanyl, illegal prescription opioids, cocaine, and other drugs in Allegheny County. Many of the arrests in today's roundup were for people considered mid-level drug dea
10/20/18 - AHPA Corrects JAMA Article That Misidentifies Illegal Drugs as Dietary Supplements
The American Herbal Products Association issued the following news release:. In a letter to the editor submitted to JAMA Open Network, American Herbal Products Association President Michael McGuffin stressed that the herbal products industry shares concerns about unapproved drugs masquerading as dietary supplements, as outlined in a recent article,
10/20/18 - Attorney General Frosh appeals to U.S. Supreme Court to uphold Maryland's law curbing drug price-gouging [The Baltimore Sun]
Oct. 19 Maryland Attorney General Brian Frosh on Friday appealed to the U.S. Supreme Court an earlier decision by a federal court that struck down a Maryland law to curb unreasonable price increases for generic drugs. In response to an industry challenge, the 4th U.S. Circuit Court of Appeals decided in April that the first-of-its-kind legislatio
10/20/18 - BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress
BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology and immunology, today disclosed additional data from the in-depth analyses of biopsies of the dual combination arm of the Phase 2 a COMBAT/KEYNOTE-202 study, evaluating patients with metastatic pancreatic adenocarcinoma treated with BL-8040 in combination with KEYTRUDA..
10/20/18 - Biopharmaceutical Contract Manufacturing Market Growth by 2027 : Boehringer Ingelheim GmbH, Patheon N.V., Rentschler Biotechnologie GmbH: Biopharmaceutical Contract Manufacturing Market Segmentation By Platform Mammalian, Microbial; By Applicatio
Valley Cottage, NY 10/19/2018 A new study by FMI titled' Biopharmaceutical Contract Manufacturing Market: Global Industry Analysis 2012 2016 and Opportunity Assessment 2017 2027', has listed out the key points being considered by Biopharmaceutical contract manufacturing companies to emerge and stay sustainably profitable in the long run
10/20/18 - Biotech IPOs For The Week Ahead
Alzheon is a U.S. clinical-stage biopharmaceutical company developing medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Alzheon has offered to sell 2.5 million shares of its common stock in the offering, and the underwriters have an option for 30 days to purchase up to 375 thousand additiona
10/20/18 - Castle Creek Pharma Announces $71.8 Million in New Investment to Expand Research for Rare Dermatologic Conditions [Tehran Times (Iran)]
Castle Creek plans to use this additional funding to support the late-stage development of an investigational drug, diacerein ointment. We are focused on developing CCP-020 as an important treatment for EBS and look forward to targeting the new investment from Fidelity and Valor towards the late-stage development of this investigational drug, said.
10/20/18 - Clearside Biomedical Appoints Veteran Supply Chain Executive, Thomas Crawford, as Vice President, Supply Chain [Palestine News Agency (WAFA)]
-Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Thomas Crawford, CSCP, as Vice President, Supply Chain. Crawfords earlier experience includes supply chain, manufacturing and trade relations management
10/20/18 - First Presentation of Early Data for Merck's Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress
Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING agonist, as monotherapy and in combination with KEYTRUDA , Merck s anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas. MK-1454 is one
10/20/18 - Generic Drugs Market with Clinical Analysis Is Expected to Grow at a CAGR of 10.0% from 2018 to 2025
Harrisburg, NC 10/19/2018 Global Generic Drugs Market Insights, Forecast To 2025; presents an in-depth assessment of the Generic Drugs including new developments, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, player profiles
10/20/18 - HeartMate 3 gets FDA approval for extended use [Star Tribune (Minneapolis)]
Oct. 20 There are more people in need of new hearts than there are hearts available that's a big reason companies like Abbott Laboratories and Medtronic sell advanced implantable pumps called left-ventricular assist devices to circulate a person's blood when their heart can't do the job alone. On Friday, Illinois- based Abbott Labs announced th
10/20/18 - Janssen Announces Three-Year TREMFYA(R) (Guselkumab) Data Demonstrates Stably Maintained Rates of Skin Clearance in Patients With Moderate to Severe Plaque Psoriasis
Janssen Pharmaceutical Companies, a subsidiary of Johnson and Johnson, issued the following news release:. The Janssen Pharmaceutical Companies of Johnson& Johnson announced today new long-term data from the open-label period of the VOYAGE 1 clinical trial demonstrating that stably maintained rates of skin clearance with TREMFYA (R) treatment achie
10/20/18 - Maryland; Baltimore; Baltimore County; Frosh appeals ruling against 'price-gouging' law; More KKK fliers turn up around neighborhood ; Goucher College president to step down in 2019
Maryland Attorney General Brian Frosh appealed Friday to the U.S. Supreme Court an earlier decision by a federal court that struck down a Maryland law to curb unreasonable price increases for generic drugs. In response to an industry challenge, the 4th U.S. Circuit Court of Appeals decided in April that the first-of-its-kind legislation violates th
10/20/18 - Merrimack Pharmaceuticals shares tumble on termination of Phase 2 trial for lung cancer treatment [Sudan Tribune]
Shares of Merrimack Pharmaceuticals Inc plunged in Fridays pre-market session after the clinical-stage oncology company announced it terminated a Phase 2 trial for its treatment of non-small cell lung cancer due to its failure to improve patients chances for survival. In the wake of the move, the Cambridge, Massachusetts- based company is starting
10/20/18 - Novotech and CNS deal expands CRO services [Tehran Times (Iran)]
Novotech, the largest Asia-Pacific- based CRO, has acquired Australasian specialist CRO Clinical Network Services, as part of a mutual mission to expand services to biopharma for early phase product development and clinical research through to later phase regional and global trials. Early phase CNS clients, wishing to advance into later phase regio
10/20/18 - Okanagan clinical team to research Alzheimers Disease drug [Syrian Arab News Agency]
The Medical Arts Health Research Group will carry out a phase 3 study in the research process, which if successful would lead next to Health Canada and U.S. Food and Drug Administration approval, with further followup research efforts carried out for the medication after public certification on a wider basis. As doctors, nurses and caregivers, find
10/20/18 - OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced interim results from its ongoing Phase 1 b trial investigating navicixizumab, OncoMed s anti-DLL4/VEGF bispecific antibody, in combination with paclitaxel in patients with...
10/20/18 - Paragon Biosciences Announces $71.8 Million in New Investment for Portfolio Company Castle Creek Pharma [Tehran Times (Iran)]
-Paragon Biosciences today announced the completion of a new capital investment of $71.8 million for Castle Creek Pharma, a Paragon portfolio company. Paragon organized the $71.8 million investment in Castle Creek from respected firms, Fidelity Management& Research Company and Valor Equity Partners, for late-stage development of treatments for rare
10/20/18 - Pharmaceutical Filtration Market Share by 2022 : Key Players AreAmazon Filters, Eaton Corporation Plc. GE Healthcare Inc.: Pharmaceutical Filtration Market Segmentation Product Type - Membrane Filters, Prefilters and Depth Media Filters, Single-use
Valley Cottage, NY 10/19/2018 Active pharmaceutical ingredients are a key component of the pharmaceutical industry in the 21st century. The manufacturing segment is expected to cross a value of more than US$ 9.3 billion by end 2022 making it imperative for companies to be present in this operation segment of the pharmaceutical filtration mark
10/20/18 - PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS TO BE PRESENTED AT 2018 ACR/ARHP ANNUAL MEETING
Chicago, October 21, 2018 0.30 CET- Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.
10/20/18 - Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting
Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a...
10/20/18 - Principia Biopharma Announces PRN1008 Receives Orphan-Drug Designation from FDA for Treatment of Immune Thrombocytopenic Purpura [Syrian Arab News Agency]
-Principia Biopharma Inc., a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that PRN1008, an oral, reversible covalent Brutons Tyrosine Kinase inhibitor, has been granted orphan-drug designation by the U.S. Food
10/20/18 - Sen. Cassidy Joins National Academy of Medicine's Discussion on Affordable Drugs
Bill Cassidy, R- Louisiana, issued the following news release:. U.S. Senator Bill Cassidy, M.D., a member of the Senate health committee, recently joined National Academy of Medicine President Victor Dzau for a panel discussion on "Affordable Medicines: Access, Innovation, and the Public Interest." The panel also featured former Lockheed Martin CEO
10/20/18 - Sens. Grassley, Warren Issue Statement on FDA Rules on Hearing Aids
Charles E. Grassley, R- Iowa, and Elizabeth Warren, R- Massachusetts, issued the following joint statement applauding the Food and Drug Administration on its action to make more affordable hearing aids available over-the-counter:. "We are pleased that the US Food and Drug Administration will prioritize issuing rules for over-the-counter hearing ai
10/20/18 - Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc
Takeda Pharmaceutical Company Limited announces that it has received unconditional clearance from the Japan Fair Trade Commission for the proposed acquisition of Shire plc announced on May 8, 2018. We are very pleased to have received unconditional clearance from the Japan Fair Trade Commission for our proposed acquisition of Shire, said Chri
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415